256 innovations from Bar-Ilan University, available for licensing, co-investment, or spin-out through BIRAD.
Onn Itay
We developed a peptide regulator that modulates the protein-protein interaction between Smc2 and Smc4 heads and blocks condensin activity. Condensin organizes interphase chromatin into mitotic chromosomes. This ensures the structural stability and segregation fidelity of chromosomes. Inhibiting condensin leads to a mitotic catastrophe and will affect cell proliferation. This property may be used to treat yeast infections and/or treat cancer directly or indirectly.
Ozana, Nisan
In some embodiments, the invention relates to a hybrid sticker-based and wearable multimodal contact sensing system incorporating both rolling shutter and global shutter optical sensors, configured to measure blood flow and tissue oxygenation, and further comprising one or more electrodes configured to measure electrical physiological responses. The multimodal sensing system may comprise a plurality of sensors configured for attachment to different anatomical locations, including the forehead, carotid region, chest, and wrist. Optical sensing at the carotid region enables high-frequency measurement of blood flow dynamics, which may be used to assess flow irregularities, turbulence, or indicators associated with vascular obstruction. A sensor positioned on the forehead may be configured to measure cerebral blood flow, while a wrist-worn sensor may be configured to provide peripheral vascular measurements. In combination, measurements from the wrist, chest, carotid, and forehead may be used to estimate physiological transit times and to derive neurovascular and cardiovascular parameters. Electrical sensing provided by the electrodes may be integrated with the optical measurements to enable multimodal physiological monitoring.
Margel Shlomo
The invention relates generally to the field of adhesive thin coatings comprising essential oils, hydrogen peroxide & ethanol and their use via a controlled release process.
Ayal Hendel
The invention utilizes CRISPR-Cas9 editing and rAAV6 vectors for transgene delivery to correct the RAG1 and RAG2 coding exon. The novelty is in the construct we use for the correction which replaces the entire open reading from of the gene as oposed to standard practice which is to insert the transgene.
Noked Malachi
Spherical LiNiO2 (LNO) is synthesized by scalable solid state route. Strategically controllable synthesis approach endowed with suppression of detrimental phase transformation. The presented approach facilitate dense LNO with controllable shape and in-situ doping option. Including also surface modification by unique ALD process for LAZO And demonstration in solid state lithium batteries
Piran Ron
The progressive loss of insulin-producing β-cells is central to the pathogenesis of all diabetes types, yet strategies for their regeneration remain limited. Here, we describe the successful implementation of a mathematical prediction we developed: inhibition of somatostatin (Sst) expression enabled robust, glucose-responsive β-cell regeneration and restored insulin independence in diabetic models. Genetic Sst knock out (SstKO) mice spontaneously recovered from chemically induced diabetes. We then rediscovered Cysteamine (Cys), an FDA-approved drug, as a pharmacological inhibitor of Sst production in mouse and human primary islets. Mechanistically, Sst suppression released a brake on intrinsic regenerative pathways within the islet. In diabetic wild-type mice, Cys reproduced the regenerative phenotype of SstKO animals. Importantly, in autoimmune-prone NOD mice, Cys treatment restored β-cell function and insulin independence. Together, these findings identify Sst inhibition as both a regenerative and therapeutic axis for β-cell regeneration, and nominate Cys as a safe, clinically translatable candidate for diabetes therapy
Danielli Amos
The invention significantly accelerate the detection time of specific DNA sequences in solution.
Shokhen Michael
I will provide some attached with this document
Cohen Cyrille
In this project, we have developed novel chimeric receptors by fusing the extracellular domain of the murine 14G2a antibody with various signaling domains and expressing them in primary human T-cells. Through our work, we identified several mutants exhibiting enhanced biological activity against breast cancer, neuroblastoma, melanoma, and other cancer types. Additionally, we demonstrated that these receptors can upregulate the activation marker 41BB. Overall, we propose that the engineering of T-cells with improved anti-GD2 chimeric receptors holds significant implications for enhancing T cell-based immunotherapy. These mutants also serve as a potential foundation for the development of antibodies or bispecific T-cell engagers (BiTEs)
Gerber Doron
We have a designed a new version of our cancer screening device. In this new version, we modified the device to work with a limited set panel of drugs (8-16). The idea is that we can take a panel of drugs the physician needs to choose from and test these drugs against cancer cells from a patient. We can then provide the physician with information on which drugs the patient's cancer cells are sensitive or resistant too. In turn the physician can now choose a more personalized therapy. The main difference from the former design is that it is not meant for hundreds of drug combinations and that it is designed with point of care diagnostics in mind.
Piran Ron
Latent autoimmune diabetes in adults (LADA) is a relatively new defined diabetes type. It has a strong autoimmune component, making it similar to type I diabetes (T1D), while its onset is at a later age (30’s or older), making it similar to type II diabetes (T2D). It is still unclear how prevalent LADA is in the general population, as most LADA patients are erroneously diagnosed with T2D receiving imprecise treatment. It is estimated that most lean T2D patients are LADA patients. Therefore, it is estimated that the percentage of LADA patients out of the T2D patients is 10%. Considering that T2D is 90% of all diabetic patients and that T1D is about 8%, making LADA more abundant than T1D (10*90/100=9% of total diabetic patients). All diabetes types eventually end in pancreatic β-cell loss and thus results in the loss of insulin secretion, which causes overproduction and a decreased cellular uptake of glucose. Therefore, developing novel strategies aiming to protect, regenerate, and restore β-cells would represent a promising therapeutic alternative for all patients with diabetes. Researches have identified several drugs which possibly stimulate β-cell proliferation and enhance their function. Among these are γ-Aminobutyric acid (GABA), dipeptidyl peptidase IV inhibitors (DPP-4i) such as Sitagliptin (SIT), or proton pump inhibitors (PPI) like Omeprazole (OMP). We found that the combined treatment (CT) administration demonstrated a significant improvement in diabetic symptoms compared to untreated mice and mice that received GABA, GABA+SIT, GABA+OMP, or SIT+OMP. Moreover, ~30% of the mice that were given CT were COMPLETELY CURED of diabetes and showed normoglycemia for 7 weeks after the last drug administration, an unprecedented achievement for this irreversible disease. We have clear indications that similar success rates also recapitulate in human LADA patients. The challenge was to differentiate the 30% cured from CT unresponsive mice. Thus, we repeated the CT experiment, this time taking blood samples from all mice after diabetes onset but before starting treatment. After the experiment, we returned to the blood samples and arranged them according to the cured/unresponsive. We identified circulating RNA markers that predict 100% response to CT, enabling the successful identification of candidates for CT.
Shor Joseph
The demand for computational performance continues to rise exponentially, while power and thermal budgets impose strict limitations on integrated circuits (ICs). Modern processors employ multiple power domains, each requiring accurate current sensing for efficient power management. Existing current sensing techniques—such as shunt, Hall-effect, and fluxgate sensors—are either too large, too power-hungry, or too slow for integration at the scale of tens or hundreds of domains within a single chip. Digital ring-oscillator (RO) sensors have been explored, but they exhibit strong non-linearity, temperature, and supply dependence, which severely limit their accuracy. This research proposes a fundamentally new approach: a differential current-controlled oscillator (CCO) amplifier, which directly converts differential current or voltage into a frequency domain signal. Unlike conventional amplifiers, the CCO itself acts as both amplifier and analog-to-frequency converter, providing a highly compact, low-power, and fast solution suitable for power-gate current sensing in advanced processors. The proposed sensor targets an accuracy better than 0.2%, conversion time below 2 μs, power consumption under 20 μW, and area smaller than 0.01 mm², yet with performance significantly surpassing existing state of-the-art designs. Novel circuit techniques are introduced for non-linearity correction, temperature compensation, and common-mode rejection, including bias trimming, replica oscillators, and chopper stabilization. Preliminary simulations of a 65nm implementation demonstrate excellent linearity, 60 dB dynamic range, and temperature- and supply-induced variation below 0.02% when using replica compensation. This project will establish a new class of analog amplifiers based on differential CCOs, enabling fine-grained, energy-efficient current sensing for multi-domain processors, GPUs, and AI accelerators. The outcomes are expected to impact both industrial and academic fields by providing a compact, low-cost, low power sensing solution for power-management architectures and extending its use to applications such as biomedical monitoring, smart-grid systems, and energy-harvesting circuits.
